Atomo Diagnostics (ASX:AT1)
We spoke to John Kelly, founder and CEO of Atomo Diagnostics (ASX: AT1), about the substantial progress the company has made over the last four years to become the world’s pre-eminent developer of easy-to-use at-home rapid diagnostics.
We’re excited about the HIV testing franchise and look forward to a good reception for the company’s emerging suite of diagnostics, including one for active syphilis. Revenue is growing at Atomo and the company is moving towards profitability.
Check out the recent research report on AT1 by Pitt Street Research!
Disclosure: Our directors own shares in AT1.
Looking for the Best ASX Life Sciences Stocks to invest in right now?
